124 related articles for article (PubMed ID: 1833953)
1. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
Biberoglu K; Gursoy R; Yildiz A
Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin releasing hormone agonist therapy and its effect on bone mass.
Nencioni T; Penotti M; Barbieri-Carones M; Ortolani S; Trevisan C; Polvani F
Gynecol Endocrinol; 1991 Mar; 5(1):49-56. PubMed ID: 1910246
[TBL] [Abstract][Full Text] [Related]
3. [Ovarian suppression by the GnRH analog buserelin in the treatment of endometriosis. Clinical, biochemical and pelviscopic studies].
Raitz von Frentz M; Schweppe KW
Geburtshilfe Frauenheilkd; 1990 Aug; 50(8):634-9. PubMed ID: 2145192
[TBL] [Abstract][Full Text] [Related]
4. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive luteinizing hormone-releasing hormone agonist treatment: preliminary report.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Fertil Steril; 1984 Oct; 42(4):644-6. PubMed ID: 6436065
[No Abstract] [Full Text] [Related]
5. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
6. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
[TBL] [Abstract][Full Text] [Related]
7. Differential reduction in the volume of leiomyoma and uterus during buserelin treatment.
Puzigaća Z; Prelević GM; Sretenović Z
Gynecol Endocrinol; 1994 Mar; 8(1):39-43. PubMed ID: 8059616
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
[TBL] [Abstract][Full Text] [Related]
9. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
Nakamura Y; Yoshimura Y
Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
[No Abstract] [Full Text] [Related]
10. [Inhibitory effect of prolactin secretion by luteinizing hormone releasing hormone agonist (buserelin)].
Inoue T; Matsuoka R; Mori H; Kigawa T
Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):745-53. PubMed ID: 3093292
[TBL] [Abstract][Full Text] [Related]
11. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
[TBL] [Abstract][Full Text] [Related]
12. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
Maheux R; Guilloteau C; Lemay A; Bastide A; Fazekas AT
Am J Obstet Gynecol; 1985 Aug; 152(8):1034-8. PubMed ID: 3927734
[TBL] [Abstract][Full Text] [Related]
13. Low-dose GnRH agonist therapy for the management of endometriosis.
Uemura T; Shirasu K; Katagiri N; Asukai K; Suzuki T; Suzuki N; Osada H; Hiroshi M
J Obstet Gynaecol Res; 1999 Oct; 25(5):295-301. PubMed ID: 10533322
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of endometriosis with the GnRH agonist buserelin (Suprecur): a multicenter study].
Schindler AE; Bühler K; Mettler L; Fuchs U; Cirkel U; Ochs H; Schweppe KW; Koch R
Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):569-73. PubMed ID: 8001754
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
Franssen AM; Willemsen WN; Corbey RS; Doesburg WH; van 't Veen AJ; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(3):221-8. PubMed ID: 1908799
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
[TBL] [Abstract][Full Text] [Related]
17. [Androgens and other hormones in buserelin therapy].
Fuchs U; Zwirner M
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
[TBL] [Abstract][Full Text] [Related]
18. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
19. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
20. Dose-related inhibition of acute luteinizing hormone response during luteinizing hormone-releasing hormone agonist treatment for uterine leiomyoma.
Maheux R; Lemay A; Turcot-Lemay L
Am J Obstet Gynecol; 1988 Feb; 158(2):361-4. PubMed ID: 3124621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
